Data from Phase 1 clinical trial in healthy volunteers show comparable pharmacokinetic, pharmacodynamic and safety…
– Grace Breeding’s bio-fertilizer will be marketed under the brand name “Addir™” as a ‘soil…
TORONTO, Ontario and CAMBRIDGE, Massachusetts, June 29, 2023 (GLOBE NEWSWIRE) — ProMIS Neurosciences Inc. (TSX:…
– Grace Breeding’s bio-fertilizer will be marketed under the brand name “Addir™” as a ‘soil…
TORONTO, Ontario and CAMBRIDGE, Massachusetts, June 29, 2023 (GLOBE NEWSWIRE) — ProMIS Neurosciences Inc. (TSX:…
Potent Antibacterial Efficacy of D-PLEX100 in In-vivo and Phase 2 Clinical Studies against a Wide…
Potent Antibacterial Efficacy of D-PLEX100 in In-vivo and Phase 2 Clinical Studies against a Wide…
CALGARY, Alberta, June 29, 2023 (GLOBE NEWSWIRE) — XORTX Therapeutics Inc. (“XORTX” or the “Company”)…
CALGARY, Alberta, June 29, 2023 (GLOBE NEWSWIRE) — XORTX Therapeutics Inc. (“XORTX” or the “Company”)…
MONTREAL, June 29, 2023 (GLOBE NEWSWIRE) — Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH)…
MONTREAL, June 29, 2023 (GLOBE NEWSWIRE) — Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH)…
Scope of Work Spans Full Range of Services including Analytical Method Transfer, Formulation Development, Process…
Scope of Work Spans Full Range of Services including Analytical Method Transfer, Formulation Development, Process…
MILAN, Italy and NEW YORK, June 29, 2023 (GLOBE NEWSWIRE) — Genenta Science (NASDAQ: GNTA),…
MILAN, Italy and NEW YORK, June 29, 2023 (GLOBE NEWSWIRE) — Genenta Science (NASDAQ: GNTA),…
WALTHAM, Mass., June 29, 2023 (GLOBE NEWSWIRE) — TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage…
WALTHAM, Mass., June 29, 2023 (GLOBE NEWSWIRE) — TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage…
Preclinical data highlights ciforadenant’s mechanism of action and synergy with immune checkpoint inhibitors Enrollment continues…
Preclinical data highlights ciforadenant’s mechanism of action and synergy with immune checkpoint inhibitors Enrollment continues…
ReSPECT-GBM Phase 1 recurrent glioblastoma trial demonstrates safety and overall survival correlation with absorbed radiation…